Yuning Hong News Today

On Monday (30 October 2023), the Australian Research Council (ARC) announced funding as part of the ARC Discovery Projects scheme.Professor Susan Dodds, Senior Deputy Vice-Chancellor (Research and Industry Engagement) said the announcement is testame

Credit: ©Science China Press Immunotherapy is a type of anti-tumor treatment and has shown great clinical success against a wide variety of malignancies in recent years. Poly(I : C), a TLR3 agonist, is the most potent type I interferon (IFN) inducer. Poly(I : C) not only directly induces tumorous apoptosis, but also stimulates tumor cells to secrete immune factors. However, the immune response rate induced by Poly(I : C) remains low in several types of malignancies and higher doses are often r...